Skip to main content
. 2012 Jan 15;2012:628070. doi: 10.1155/2012/628070

Figure 1.

Figure 1

Passive and active immunotherapeutic approaches to beta-amyloid clearance. Beta-amyloid immunotherapeutic compounds currently in clinical trials utilize anti-beta-amyloid antibodies, generated through either passive or active immunotherapy approaches (left), to target beta amyloid and promote its clearance from the brain and proteolysis (right), potentially reversing the neuropathology that leads to cognitive dysfunction. Aβ: beta amyloid.